Early research (Phase 1)Study completedNCT01176474
What this trial is testing
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
Who this might be right for
Melanoma (Skin)
H. Lee Moffitt Cancer Center and Research Institute 73